AP2007004189A0 - Ghrelin binding nucleic acids - Google Patents

Ghrelin binding nucleic acids

Info

Publication number
AP2007004189A0
AP2007004189A0 AP2007004189A AP2007004189A AP2007004189A0 AP 2007004189 A0 AP2007004189 A0 AP 2007004189A0 AP 2007004189 A AP2007004189 A AP 2007004189A AP 2007004189 A AP2007004189 A AP 2007004189A AP 2007004189 A0 AP2007004189 A0 AP 2007004189A0
Authority
AP
ARIPO
Prior art keywords
nucleic acids
binding nucleic
ghrelin binding
ghrelin
acids
Prior art date
Application number
AP2007004189A
Other languages
English (en)
Inventor
Dirk Eulberg
Steffen Helmling
Sven Klussmann
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of AP2007004189A0 publication Critical patent/AP2007004189A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
AP2007004189A 2005-04-08 2006-04-10 Ghrelin binding nucleic acids AP2007004189A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05007795 2005-04-08
PCT/EP2006/003276 WO2006108599A2 (fr) 2005-04-08 2006-04-10 Acides nucleiques se liant a la ghreline

Publications (1)

Publication Number Publication Date
AP2007004189A0 true AP2007004189A0 (en) 2007-10-31

Family

ID=37087373

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004189A AP2007004189A0 (en) 2005-04-08 2006-04-10 Ghrelin binding nucleic acids

Country Status (24)

Country Link
US (2) US8101734B2 (fr)
EP (1) EP1866412A2 (fr)
JP (2) JP5308813B2 (fr)
KR (1) KR20080009072A (fr)
CN (1) CN101189337B (fr)
AP (1) AP2007004189A0 (fr)
AR (1) AR052741A1 (fr)
AU (1) AU2006233647A1 (fr)
BR (1) BRPI0608180A2 (fr)
CA (1) CA2605377A1 (fr)
CR (1) CR9423A (fr)
DO (1) DOP2006000085A (fr)
EA (1) EA200701901A1 (fr)
GB (1) GB2439673A (fr)
GT (1) GT200600137A (fr)
IL (1) IL186085A0 (fr)
MA (1) MA29384B1 (fr)
MX (1) MX2007012419A (fr)
NL (2) NL1031538C2 (fr)
PE (1) PE20061358A1 (fr)
TN (1) TNSN07375A1 (fr)
TW (1) TW200718781A (fr)
UY (1) UY29460A1 (fr)
WO (1) WO2006108599A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013274A2 (fr) * 2002-08-01 2004-02-12 Noxxon Pharma Ag Acides nucleiques a liaison de ghreline
US20070031840A1 (en) * 2003-11-10 2007-02-08 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP2439212B1 (fr) 2008-05-02 2016-12-21 Novartis AG Molécules de liaison améliorées à base de fibronectine et utilisations associées
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2011051327A2 (fr) 2009-10-30 2011-05-05 Novartis Ag Petites protéines à chaîne unique de type anticorps
WO2011051466A1 (fr) 2009-11-02 2011-05-05 Novartis Ag Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
WO2011092233A1 (fr) 2010-01-29 2011-08-04 Novartis Ag Conjugaison de levures pour produire des combinaisons de liants à base de fibronectine à haute affinité
AU2012279237B2 (en) 2011-07-01 2016-09-29 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2014085365A2 (fr) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
JP6403685B2 (ja) 2012-12-27 2018-10-17 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
WO2015070060A1 (fr) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Méthodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20160101073A (ko) 2013-12-20 2016-08-24 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
MX2017004838A (es) 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
WO2016100977A1 (fr) 2014-12-19 2016-06-23 The Broad Institute Inc. Procédés pour le profilage du répertoire de récepteurs de cellules t
WO2016100975A1 (fr) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CN116196401A (zh) 2015-05-20 2023-06-02 博德研究所 共有的新抗原
EP3302547A1 (fr) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
EP3341012A4 (fr) 2015-08-25 2019-03-20 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
FI3580561T3 (fi) 2017-02-12 2023-12-12 Biontech Us Inc Hla-pohjaiset menetelmät ja koostumukset sekä niiden käyttö
WO2019094268A1 (fr) 2017-11-10 2019-05-16 Armo Biosciences, Inc. Compositions et procédés d'utilisation de l'interleukine-10 en association avec des inhibiteurs de voies de points de contrôle immunitaire
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
US20210347842A1 (en) 2018-06-19 2021-11-11 Eli Lilly And Company Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (fr) 2018-12-17 2020-06-25 The Broad Institute, Inc. Méthodes d'identification de néo-antigènes
AU2019404547A1 (en) 2018-12-21 2021-07-22 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
EP3984595A4 (fr) * 2019-06-11 2023-08-16 Ajinomoto Co., Inc. Peptide et son utilisation
WO2020252039A1 (fr) 2019-06-12 2020-12-17 Biontech Us Inc. Compositions de néoantigènes et utilisations associées
JP2024501482A (ja) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド がん免疫療法のための組織特異的抗原
WO2024077256A1 (fr) 2022-10-07 2024-04-11 The General Hospital Corporation Procédés et compositions pour la découverte à haut débit de protéines de liaison ciblant un peptide-cmh

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
JPH11505527A (ja) 1995-05-03 1999-05-21 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 鏡像異性体リガンドの同定
DE19808591C2 (de) 1998-02-28 2000-02-03 Univ Leipzig Standardisierter durchflußzytometrischer Vollblutassay
EP1286697A2 (fr) 2000-05-17 2003-03-05 Eli Lilly And Company Procede d'inhibition selective de la ghreline
US20030211967A1 (en) 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
DK2431377T3 (en) * 2001-10-26 2017-08-14 Noxxon Pharma Ag Modified L-nucleic acids
WO2004013274A2 (fr) * 2002-08-01 2004-02-12 Noxxon Pharma Ag Acides nucleiques a liaison de ghreline
US20070031840A1 (en) 2003-11-10 2007-02-08 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
TNSN07375A1 (fr) 2009-03-17
NL1033520C2 (nl) 2010-01-21
US8101734B2 (en) 2012-01-24
US20120115937A1 (en) 2012-05-10
JP5308813B2 (ja) 2013-10-09
GB2439673A (en) 2008-01-02
PE20061358A1 (es) 2007-01-13
NL1031538C2 (nl) 2007-03-20
CN101189337A (zh) 2008-05-28
CA2605377A1 (fr) 2006-10-19
KR20080009072A (ko) 2008-01-24
US20060258607A1 (en) 2006-11-16
GB0719489D0 (en) 2007-11-21
WO2006108599A2 (fr) 2006-10-19
CR9423A (es) 2007-12-17
NL1031538A1 (nl) 2006-10-10
GT200600137A (es) 2006-11-22
IL186085A0 (en) 2008-01-20
MX2007012419A (es) 2007-12-05
AU2006233647A2 (en) 2008-04-17
AR052741A1 (es) 2007-03-28
MA29384B1 (fr) 2008-04-01
TW200718781A (en) 2007-05-16
JP2013176372A (ja) 2013-09-09
JP2008534024A (ja) 2008-08-28
EP1866412A2 (fr) 2007-12-19
CN101189337B (zh) 2013-11-06
DOP2006000085A (es) 2006-11-15
UY29460A1 (es) 2006-11-30
EA200701901A1 (ru) 2008-04-28
AU2006233647A1 (en) 2006-10-19
BRPI0608180A2 (pt) 2009-11-17
NL1033520A1 (nl) 2007-08-06
WO2006108599A3 (fr) 2007-02-15

Similar Documents

Publication Publication Date Title
IL186085A0 (en) Ghrelin binding nucleic acids
EP1910534A4 (fr) Chimères de polymérase-protéine de liaison adn
ZA201301416B (en) Binding molecules
EP1827245A4 (fr) Composant de liaison
IL175443A0 (en) Nucleic acids specifically binding bioactive ghrelin
GB0510790D0 (en) Anti-CD16 binding molecules
GB0521991D0 (en) Siglec-9 binding agents
PL2041282T3 (pl) Kwasy nukleinowe wiążące sdf-i
IL181330A0 (en) Thiazolo-naphthyl acids
EP1736282A4 (fr) Agrafeuse
EP1779977A4 (fr) Agrafeuse
EP1795306A4 (fr) Agrafeuse
IL184137A0 (en) Binding implement for document
GB0520523D0 (en) Object binding
EP1704968A4 (fr) Agrafeuse
GB2428622B (en) Stapler
EP1942012A4 (fr) Attache
GB0410627D0 (en) Specific binding members
AU302199S (en) Stapler
GB2428623B (en) Stapler
EP1767314A4 (fr) Agrafeuse
EP1787759A4 (fr) Agrafeuse
GB0525885D0 (en) Object binding
GB0520934D0 (en) Object binding
GB0502913D0 (en) Binding sites